Serial No.: To Be Assigned Filed : Herewith

Page : 3 of 16

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of formula (I) or a pharmaceutically acceptable salt thereof:

in which:

X is halogen, cyano, nitro, S(O)_nR⁶ or C₁₋₄alkyl which is substituted by one or more halogen atoms;

Y is selected from hydrogen, halogen, CN, nitro, SO₂R³, OR⁴, SR⁴, SOR³, SO₂NR⁴R⁵, CONR⁴R⁵, NR⁴R⁵, NR⁶SO₂R³, NR⁶CO₂R⁶, NR⁶COR³, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇ cycloalkyl or C₁₋₆alkyl, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, OR⁶ and NR⁶R⁷, S(O)_nR⁶; where n is 0, 1 or 2;

Z is aryl or a ring A, where A is a six membered heterocyclic aromatic ring containing one or more nitrogen atoms or may be a 6,6 or 6,5 fused bicycle containing one or more O, N, S atoms,

Applicant: Bonnert et al.
Serial No.: To Be Assigned

Filed: Herewith Page: 4 of 16

the aryl or A rings all being optionally substituted by one or more substituents independently selected from from hydrogen, halogen, CN, OH, SH, nitro, COR⁹, CO₂R⁶, SO₂R⁹, OR⁹, SR⁹, SOR⁹, SO₂NR¹⁰R¹¹, CONR¹⁰R¹¹, NR¹⁰R¹¹, NHSO₂R⁹, NR⁹SO₂R⁹, NR⁶CO₂R⁶, NHCOR⁹, NR⁹COR⁹, NR⁶CONR⁴R⁵, NR⁶SO₂NR⁴R⁵, aryl, heteroaryl,

 C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_7 cycloalkyl or C_{1-6} alkyl, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, C_3 - C_7 cycloalkyl, OR^6 , NR^6R^7 , $S(O)_nR^6$ (where n is 0, 1 or 2), $CONR^6R^7$, NR^6COR^7 , $SO_2NR^6R^7$ and $NR^6SO_2R^7$.

 R^1 and R^2 independently represent a hydrogen atom, halogen, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_7 cycloalkyl or a C_{1-6} alkyl group, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, C_3 - C_7 cycloalkyl, NR^6R^7 , OR^6 , $S(O)_nR^6$ (where n is 0, 1 or 2);

or

R¹ and R² together can form a 3-8 membered ring optionally containing one or more atoms selected from O, S, NR⁶ and itself optionally substituted by one or more C₁-C₃ alkyl or halogen;

 R^3 represents C_3 - C_7 cycloalkyl or C_{1-6} alkyl which may be optionally substituted by one or more substituents independently selected from halogen, C_3 - C_7 cycloalkyl, OR^6 and NR^6R^7 , $S(O)_nR^6$ (where n = 0,1 or 2), $CONR^6R^7$, NR^6COR^7 , $SO_2NR^6R^7$ and $NR^6SO_2R^7$;

 R^4 and R^5 independently represent hydrogen, C_3 - C_7 cycloalkyl or C_{1-6} alkyl, the latter two groups being optionally substituted by one or more substituents independently selected from halogen, C_3 - C_7 cycloalkyl, OR^6 and NR^6R^7 , $S(O)_nR^6$ (where n=0,1 or 2), $CONR^6R^7$, NR^6COR^7 , $SO_2NR^6R^7$ and $NR^6SO_2R^7$;

Serial No.: To Be Assigned Filed: Herewith

Filed : Herewith Page : 5 of 16

or

 R^4 and R^5 together with the nitrogen atom to which they are attached can form a 3-8 membered saturated heterocylic ring optionally containing one or more atoms selected from O, $S(O)_n$ (where n = 0,1 or 2), NR^8 , and itself optionally substituted by halogen or C_{1-3} alkyl;

R⁶ and R⁷ independently represents a hydrogen atom or C₁-C₆ alkyl;

R⁸ is hydrogen, C₁-4 alkyl, -COC₁-C₄ alkyl, CO₂C₁-C₄alkyl or CONR⁶C₁-C₄alkyl;

 R^9 represents aryl, heteroaryl, C_3 - C_7 cycloalkyl or C_{1-6} alkyl, the latter two groups may be optionally substituted by one or more substituents independently selected from halogen, C_3 - C_7 cycloalkyl, aryl, heteroaryl OR^6 and NR^6R^7 , $S(O)_nR^6$ (where n=0, 1 or 2), $CONR^6R^7$, NR^6COR^7 , $SO_2NR^6R^7$ and $NR^6SO_2R^7$;

 R^{10} and R^{11} independently represent aryl or heteroaryl, hydrogen, C_3 - C_7 cycloalkyl or C_{1-6} alkyl, the latter two groups being optionally substituted by one or more substituents independently selected from halogen, C_3 - C_7 cycloalkyl, aryl, heteroaryl, OR^6 and NR^6R^7 , $S(O)_nR^6$ (where n=0, 1 or 2), $CONR^6R^7$, NR^6COR^7 , $SO_2NR^6R^7$ and $NR^6SO_2R^7$;

or

 R^{10} and R^{11} together with the nitrogen atom to which they are attached can form a 3-8 membered saturated heterocylic ring optionally containing one or more atoms selected from O, $S(O)_n$ (where n=0, 1 or 2), NR^8 , and itself optionally substituted by halogen or C_1 - C_3 alkyl.

2. (Currently amended) A compound according to claim 1 in which X is halogen, cyano, nitro, $S(O)_nR^6$ or C_{1-4} alkyl which is substituted by one or more halogen atoms[[;]].

Applicant: Bonnert et al.
Serial No.: To Be Assigned
Filed: Herewith

Filed: Herewith Page: 6 of 16

3. (Original) A compound according to claim 1 in which X is trifluoromethyl, nitro, cyano or halogen.

- 4. (Currently amended) A compound according to claim 1 any one of claims 1 to 3 in which Y is hydrogen, halogen or C_{1-3} alkyl.
- 5. (Currently amended) A compound according to <u>claim 1</u> any one of claims 1 to 4 in which Z is phenyl, pyridinyl, pyrimidyl, naphthyl, quinolyl, benzo[b]thienyl or benzofuranyl each optionally substituted with substituents as defined in claim 1.
- 6. (Currently amended) A compound according to <u>claim 1</u> any one of claims 1 to 4 in which Z is phenyl optionally substituted with substituents as defined in claim 1.
- 7. (Currently amended) A compound according to <u>claim 1</u>-any one of claims 1 to 6 in which both R^1 and R^2 are hydrogen or one is hydrogen and the other is methyl or ethyl or both are methyl.
- 8. (Currently amended) A compound according to <u>claim 1 any one of claims 1 to 7</u> selected from:
- {[5-Chloro-4'-(ethylthio)biphenyl-2-yl]oxy}acetic acid,
- {[5-Chloro-4'-(ethylsulfonyl)biphenyl-2-yl]oxy}acetic acid.
- [(4',5-Dichlorobiphenyl-2-yl)oxy]acetic acid,
- [(5-Chloro-4'-cyanobiphenyl-2-yl)oxy]acetic acid,
- [(5-Chloro-4'-methoxybiphenyl-2-yl)oxy]acetic acid,
- (4-Chloro-2-quinolin-8-ylphenoxy)acetic acid,
- [(5-Chloro-3',4'-dimethoxybiphenyl-2-yl)oxylacetic acid.
- 2'-(Carboxymethoxy)-5'-chlorobiphenyl-4-carboxylic acid,

Serial No.: To Be Assigned

Filed : Herewith Page : 7 of 16

{[5-Chloro-4'-(methylsulfonyl)biphenyl-2-yl]oxy}acetic acid,

{[5-Chloro-4'-(ethylsulfonyl)-2'-methylbiphenyl-2-yl]oxy} acetic acid,

[(5-Cyanobiphenyl-2-yl)oxy]acetic acid,

[(5-Nitrobiphenyl-2-yl)oxy]acetic acid,

{[4'-(Methylthio)-5-(trifluoromethyl)biphenyl-2-yl]oxy}acetic acid,

{[4'-(Methylsulfonyl)-5-(trifluoromethyl)biphenyl-2-yl]oxy}acetic acid,

{[4'-(Ethylsulfonyl)-2'-methyl-5-(trifluoromethyl)biphenyl-2-yl]oxy}acetic acid,

(4-Chloro-2-pyrimidin-5-ylphenoxy)acetic acid,

{2-[5-(Aminosulfonyl)pyridin-2-yl]-4-chlorophenoxy}acetic acid,

[2-(2-Aminopyrimidin-5-yl)-4-chlorophenoxy]acetic acid, trifluoroacetate salt,

[4-Chloro-2-(4-methyl-2-morpholin-4-ylpyrimidin-5-yl)phenoxy]acetic acid,

{4-Chloro-2-[2-(dimethylamino)pyrimidin-5-yl]phenoxy} acetic acid,

[4-Chloro-2-(2-morpholin-4-ylpyrimidin-5-yl)phenoxy]acetic acid,

{4-Chloro-2-[2-(methylamino)pyrimidin-5-yl]phenoxy}acetic acid,

{2-[2-(Benzylamino)pyrimidin-5-yl]-4-chlorophenoxy} acetic acid,

[4-Chloro-2-(2-piperidin-1-ylpyrimidin-5-yl)phenoxy]acetic acid,

(4-Chloro-2-{2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}phenoxy)acetic acid,

[[2',5-Dichloro-4'-(ethylsulfonyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[2'-Chloro-4'-(ethylsulfonyl)-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[5-Chloro-4'-(ethylsulfonyl)-2'-fluoro[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4'-(Ethylsulfonyl)-2'-fluoro-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]-acetic acid,

[[5-Chloro-4'-(ethylsulfonyl)-2'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

2-[[5-Chloro-4'-(ethylsulfonyl)[1,1'-biphenyl]-2-yl]oxy]-propanoic acid,

2-[[4'-(Ethylsulfonyl)-2'-methyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]-(2S)- propanoic acid,

2-[[4'-(Ethylsulfonyl)-2'-methyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]-(2R)- propanoic acid,

2-[[2',5-Dichloro-4'-(ethylsulfonyl)[1,1'-biphenyl]-2-yl]oxy]-(2S)- propanoic acid,

Applicant: Bonnert et al. Serial No.: To Be Assigned

Filed: Herewith Page: 8 of 16

2-[[2'-Chloro-4'-(ethylsulfonyl)-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]-(2S)- propanoic acid,

2-[[4'-(Ethylsulfonyl)-2'-methyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]-2-methyl-propanoic acid,

2-[[4'-(Ethylsulfonyl)-2'-methyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]-butanoic acid,

[4-Chloro-2-[2-[(methylsulfonyl)(phenylmethyl)amino]-5-pyrimidinyl]phenoxy]-acetic acid,

[4-Chloro-2-[2-[(ethylsulfonyl)(phenylmethyl)amino]-5-pyrimidinyl]phenoxy]-acetic acid,

[2-[2-[Acetyl(phenylmethyl)amino]-5-pyrimidinyl]-4-chlorophenoxy]-acetic acid,

[[4'-(Ethylsulfonyl)-5-fluoro-2'-methyl[1,1'-biphenyl]-2-yl]oxy]-acetic acid,

[[4'-(Ethylsulfonyl)-4,5-difluoro-2'-methyl[1,1'-biphenyl]-2-yl]oxy]-acetic acid,

[[4'-(Ethylsulfonyl)-3,5-difluoro-2'-methyl[1,1'-biphenyl]-2-yl]oxy]-acetic acid,

[2-(2-Amino-5-methyl-3-pyridinyl)-4-(trifluoromethyl)phenoxy]- acetic acid,

[[4'-Amino-2'-methyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4'-Amino-2'-chloro-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[2'-Chloro-4'-hydroxy-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[2-(2,4-Dimethoxy-5-pyrimidinyl)-4-(trifluoromethyl)phenoxy]- acetic acid,

[[2'-Chloro-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[2',5-Bis(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[5'-Fluoro-2'-methoxy-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[5'-Cyano-2'-methoxy-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4'-Chloro-2'-methyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[2',5'-Dimethyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[5'-Chloro-2'-methyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[2'-Fluoro-6'-methyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4'-Fluoro-2'-methyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4'-[[(Ethylamino)carbonyl]amino]-2'-methyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]-acetic acid,

Applicant: Bonnert et al. Serial No.: To Be Assigned

Filed : Herewith Page : 9 of 16

[[2'-Methyl-4'-[[(methylamino)carbonyl]amino]-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]-acetic acid,

[[4'-[[(Cyclopropylamino)carbonyl]amino]-2'-methyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[2'-Methyl-4'-[[(propylamino)carbonyl]amino]-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]-acetic acid,

[[2',4'-Dimethyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[5'-Fluoro-2'-methyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4'-(Aminocarbonyl)-2'-methyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[3'-Fluoro-2'-methyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[2',5'-Difluoro-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[5'-(Aminosulfonyl)-2'-chloro-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4'-Cyano-2'-methyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4'-Chloro-2'-fluoro-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[2',5'-Difluoro-4'-methoxy-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[2'-fluoro-5'-methyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[2'-Fluoro-4'-methyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4'-Methoxy-2'-methyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4'-(Aminosulfonyl)-2',5'-difluoro-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[2-Benzo[b]thien-3-yl-4-(trifluoromethyl)phenoxy]- acetic acid,

[2-(2-Benzofuranyl)-4-(trifluoromethyl)phenoxy]- acetic acid,

[[4'-Chloro-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[3'-(1-Methylethyl)-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[3',4'-Difluoro-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[2-(1,3-Benzodioxol-5-yl)-4-(trifluoromethyl)phenoxy]- acetic acid,

[[4'-Ethyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[3'-Fluoro-5-(trifluoromethyl)[1,1':4',1"-terphenyl]-2-yl]oxy]- acetic acid,

[[4'-(Trifluoromethoxy)-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

Applicant: Bonnert et al.
Serial No.: To Be Assigned
Filed Horovith

Filed : Herewith Page : 10 of 16

```
[[2',3'-Dichloro-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,
```

[[4'-(1,1-Dimethylethyl)-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[2-(6-Methoxy-2-naphthalenyl)-4-(trifluoromethyl)phenoxy]- acetic acid,

[[4'-(Ethylthio)-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4'-Acetyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[2-(2-Chloro-5-methyl-4-pyridinyl)-4-(trifluoromethyl)phenoxy]- acetic acid,

[[5'-(Aminosulfonyl)-2'-methyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[2-(8-Quinolinyl)-4-(trifluoromethyl)phenoxy]- acetic acid,

[[3'-Cyano-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[2-[4-Methyl-6-[methyl(methylsulfonyl)amino]-3-pyridinyl]-4-(trifluoromethyl) phenoxy]-acetic acid,

[[2'-Methyl-5'-(methylsulfonyl)-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

2'-(Carboxymethoxy)-5'-(trifluoromethyl)-[1,1'-biphenyl]-3-carboxylic acid, 3-methyl ester.

2'-(Carboxymethoxy)-5'-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxylic acid, 2-methyl ester,

[[5-(Trifluoromethyl)[1,1':4',1"-terphenyl]-2-yl]oxy]- acetic acid,

[[3'-Fluoro-2',4'-dimethyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[2'-Nitro-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[2'-Methyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[3'-Chloro-2'-methyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[5-(Trifluoromethyl)[1,1':3',1"-terphenyl]-2-yl]oxy]- acetic acid,

2'-(Carboxymethoxy)-5'-(trifluoromethyl)-[1,1'-biphenyl]-4-carboxylic acid, 4-methyl ester,

[[4'-Nitro-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[5-(Trifluoromethyl)-3'-[(trifluoromethyl)thio][1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[5-(Trifluoromethyl)-4'-[(trifluoromethyl)thio][1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4'-Methyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4'-Fluoro-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[3'-Fluoro-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[3'-Methyl-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

Applicant: Bonnert et al.
Serial No.: To Be Assigned

Filed: Herewith Page: 11 of 16

```
[2-(3-Pyridinyl)-4-(trifluoromethyl)phenoxy]- acetic acid,
```

[[2'-Fluoro-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[2'-Methoxy-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[3'-Methoxy-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4'-Methoxy-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[3'-(Ethylsulfonyl)-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[3'-Propoxy-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4'-Propoxy-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[2-(2-Amino-4-methyl-5-pyrimidinyl)-4-(trifluoromethyl)phenoxy]- acetic acid,

[[4'-Cyano-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4',5-Bis(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[2-(2-Naphthalenyl)-4-(trifluoromethyl)phenoxy]- acetic acid,

[[4'-(1-Pyrrolidinylsulfonyl)-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4'-[(Dimethylamino)sulfonyl]-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4'-[[(Phenylmethyl)amino]sulfonyl]-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4'-[[(2,2,2-Trifluoroethyl)amino]sulfonyl]-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4'-[[(5-Methyl-2-thiazolyl)amino]sulfonyl]-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4'-[(Phenylamino)sulfonyl]-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4'-[(Diethylamino)sulfonyl]-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4'-[(Cyclopropylamino)sulfonyl]-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4'-(Aminosulfonyl)-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4'-[(Methylamino)sulfonyl]-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[[4'-[(4-Methyl-1-piperazinyl)sulfonyl]-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]- acetic acid,

[2-[4-Methyl-2-(5-methyl-1,1-dioxido-1,2,5-thiadiazolidin-2-yl)-5-pyrimidinyl]-4-(trifluoromethyl)phenoxyl- acetic acid,

Applicant: Bonnert et al.
Serial No.: To Be Assigned

Filed : Herewith Page : 12 of 16

- [2-[4-Methyl-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-4-(trifluoromethyl)phenoxy]-acetic acid,
- [2-[2-(1,1-Dioxido-2-isothiazolidinyl)-4-methyl-5-pyrimidinyl]-4-(trifluoromethyl)phenoxy]-acetic acid, ammonium salt,
- [2-[2-(3-Hydroxy-1-azetidinyl)-4-methyl-5-pyrimidinyl]-4-(trifluoromethyl)phenoxy]- acetic acid,
- [2-[4-Methyl-2-(4-methyl-1-piperazinyl)-5-pyrimidinyl]-4-(trifluoromethyl)phenoxy]- acetic acid,
- [2-[4-Methyl-2-(1-pyrrolidinyl)-5-pyrimidinyl]-4-(trifluoromethyl)phenoxy]- acetic acid,
- [2-[2-(Dimethylamino)-4-methyl-5-pyrimidinyl]-4-(trifluoromethyl)phenoxy]- acetic acid,
- [2-[5-Methyl-2-[methyl(methylsulfonyl)amino]-4-pyrimidinyl]-4-(trifluoromethyl)phenoxy]-acetic acid,
- [2-[2-[[(Dimethylamino)sulfonyl]amino]-4-methyl-5-pyrimidinyl]-4-(trifluoromethyl)phenoxy]-acetic acid,
- [[2'-Chloro-4'-[(methoxycarbonyl)amino]-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]acetic acid
- 2-[[2'-Chloro-4'-(methylsulfonyl)-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]-(2S)- propanoic acid,
- 2-[[3'-Cyano-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,
- 2-[[4'-[(Dimethylamino)sulfonyl]-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]-(2S)- propanoic acid,
- 2-[[2'-Chloro-4'-[(dimethylamino)sulfonyl]-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,
- 2-[[2'-Fluoro-4'-(methylsulfonyl)-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]-(2S)- propanoic acid,
- [[2',5-Dichloro-4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,
- [[5-Chloro-4'-[(dimethylamino)sulfonyl][1,1'-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,
- [[2',5-Dichloro-4'-[(dimethylamino)sulfonyl][1,1'-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

Serial No.: To Be Assigned
Filed: Herewith
Page: 13 of 16

[(5-Chloro-3'-cyano[1,1'-biphenyl]-2-yl)oxy]-(2S)-propanoic acid,

[[5-Chloro-4'-[(dimethylamino)sulfonyl]-2'-fluoro[1,1'-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

[[5-Chloro-4'-(4-morpholinylsulfonyl)[1,1'-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

[[5-Chloro-2'-fluoro-4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

2-[[4'-(1-Azetidinylsulfonyl)-5-chloro[1,1'-biphenyl]-2-yl]oxy]-(2\$)-propanoic acid,

2-[[5-Chloro-2'-methyl-4'-(1-pyrrolidinylcarbonyl)[1,1'-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

2-[(2',4'-Dichloro-5-cyano[1,1'-biphenyl]-2-yl)oxy]-(2S)-propanoic acid,

2-[[5-Cyano-2'-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

2-[(3'-Cyano-5-fluoro[1,1'-biphenyl]-2-yl)oxy]-(2\$)-propanoic acid, sodium salt,

2-[(2',4'-Dichloro-5-fluoro[1,1'-biphenyl]-2-yl)oxy]-(2S)-propanoic acid, sodium salt,

2-[[2'-Chloro-5-fluoro-4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl]oxy]-(2S)-propanoic acid

2-[[2'-Chloro-5-fluoro-5'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

[[4'-(Ethylsulfonyl)-6-methyl-5-nitro[1,1'-biphenyl]-2-yl]oxy]acetic acid,

[[5-Chloro-4'-(ethylsulfonyl)-6-methyl[1,1'-biphenyl]-2-yl]oxy]acetic acid,

[[4'-(Methylsulfonyl)-2',5-bis(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]acetic acid,

2-[4-Chloro-2-[4-methyl-6-[methyl(methylsulfonyl)amino]-3-pyridinyl]phenoxy]-(2S)-propanoic acid,

2-[2-[4-Methyl-2-[(methylsulfonyl)amino]-5-pyrimidinyl]-4-(trifluoromethyl)phenoxy]-(2S)-propanoic acid,

[(5-Chloro-3'-cyano[1,1'-biphenyl]-2-yl)oxy]- acetic acid, and pharmaceutically acceptable salts thereof.

9. (Cancelled)

10. (Currently amended) A method of treating a disease mediated by prostaglandin D2, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt as defined in <u>claim 1-claims 1 to 8</u>.

Serial No.: To Be Assigned

Filed : Herewith Page : 14 of 16

11. (Currently amended) A méthod of treating a respiratory disease, such as asthma and rhinitis, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as defined in claim 1-claims 1-to-8.

- 12. (New) The method according to claim 11, where in the respiratory disease is asthma or rhinitis.
- 13. (New) A compound according to claim 2, in which Y is hydrogen, halogen or C₁₋₃alkyl.
- 14. (New) A compound according to claim 2, in which Z is phenyl, pyridinyl, pyrimidyl, naphthyl, quinolyl, benzo[b]thienyl or benzofuranyl each optionally substituted with substituents as defined in claim 1.
- 15. (New) A compound according to claim 2, in which Z is phenyl optionally substituted with substituents as defined in claim 1.
- 16. (New) A compound according to claim 2, in which both R¹ and R² are hydrogen or one is hydrogen and the other is methyl or ethyl or both are methyl.
- 17. (New) A compound according to claim 3, in which Y is hydrogen, halogen or C₁₋₃alkyl.
- 18. (New) A compound according to claim 3, in which Z is phenyl, pyridinyl, pyrimidyl, naphthyl, quinolyl, benzo[b]thienyl or benzofuranyl each optionally substituted with substituents as defined in claim 1.
- 19. (New) A compound according to claim 3, in which Z is phenyl optionally substituted with substituents as defined in claim 1.

Serial No.: To Be Assigned Filed: Herewith Page: 15 of 16

-1

20. (New) A compound according to claim 3, in which both R^1 and R^2 are hydrogen or one is hydrogen and the other is methyl or both are methyl.